IMR Press / FBL / Volume 12 / Issue 8 / DOI: 10.2741/2285

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article
Plasminogen activator inhibitor (PAI)-1 in vascular inflammation and thrombosis
Show Less
1 Department of Internal Medicine, Koshigaya Hospital, Dokkyo Medical University, Saitama, Japan
Academic Editor:Arthur Chu
Front. Biosci. (Landmark Ed) 2007, 12(8), 2957–2966;
Published: 1 May 2007
(This article belongs to the Special Issue Blood coagulation, inflammation, and thrombosis)

Impaired fibrinolysis may be associated with development of atherothrombotic cardiovascular disease (CVD) in metabolic syndrome or type 2 diabetes. Plasma plasminogen activator inhibitor (PAI)-1, a potent inhibitor of fibrinolysis, is elevated in a number of clinical situations that are associated with high incidence of CVD. Impaired fibrinolysis resulting from high plasma PAI-1 can lead to excessive fibrin accumulation within vessels, resulting in atherothrombosis. Increased expression of PAI-1 is found in atherosclerotic lesions in humans, especially atherosclerotic plaques in patients with type 2 diabetes. This increased vascular expression of PAI-1 promotes neointima formation via accumulation of fibrin or fibrinogen as a result of inhibited clearance of platelet-fibrin thrombi. PAI-1, an acute phase protein, also could be involved in vascular inflammation. PAI-1 may be associated not only systemically but also locally with development of CVD.

Back to top